| Balance Sheet Account Details |
Balance Sheet Account Details Accounts Receivable | | | | | | | | | | | | | | June 30,
2022 | | | December 31,
2021 | | Accounts receivable, net: | | | | | | Accounts receivable, trade | $ | 5,314,000 | | | | $ | 5,624,000 | | | Less allowance for doubtful accounts | (463,000) | | | | (690,000) | | | $ | 4,851,000 | | | | $ | 4,934,000 | |
Inventory The components of inventories are as follows: | | | | | | | | | | | | | | June 30,
2022 | | December 31,
2021 | | Inventory: | | | | | Raw materials | $ | 837,000 | | | $ | 745,000 | | | Finished goods | 19,754,000 | | | 11,642,000 | | | $ | 20,591,000 | | | $ | 12,387,000 | |
Intangible Assets Intangible assets that are subject to amortization consisted of the following for the periods presented: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | June 30, 2022 | | December 31, 2021 | | | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount | | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount | | Trade name | | $ | 1,630,000 | | | $ | (372,000) | | | $ | 1,258,000 | | | $ | 1,630,000 | | | $ | (210,000) | | | $ | 1,420,000 | | | Customer relationships | | 3,950,000 | | | (773,000) | | | 3,177,000 | | | 3,950,000 | | | (378,000) | | | 3,572,000 | | | Developed technology | | 22,800,000 | | | (3,230,000) | | | 19,570,000 | | | 22,800,000 | | | (950,000) | | | 21,850,000 | | | Intangibles, net | | $ | 28,380,000 | | | $ | (4,375,000) | | | $ | 24,005,000 | | | $ | 28,380,000 | | | $ | (1,538,000) | | | $ | 26,842,000 | |
Accrued Expenses Accrued expenses consist of the following: | | | | | | | | | | | | | June 30,
2022 | | December 31,
2021 | | Compensation expenses | $ | 4,861,000 | | | $ | 4,529,000 | | | Goods received not invoiced | 1,238,000 | | | 1,073,000 | | | Customer deposits | 73,000 | | | 826,000 | | | Taxes payable | 722,000 | | | 677,000 | | | Insurance | — | | | 1,011,000 | | | Professional fees and royalties | 368,000 | | | 288,000 | | | Warranty liabilities | 175,000 | | | 175,000 | | | Accrued clinical study fees | 169,000 | | | 1,000 | | | Other | 154,000 | | | 1,114,000 | | | Total | $ | 7,760,000 | | | $ | 9,694,000 | |
|